Te hacen una pregunta comprometida y no sabes responderla. Típico de cualquier sectarismo eclesiástico cuando se les mencionan las teorías de la evolución.

"Céntrate en Dios, hijo mío, y olvida la ciencia porque todo lo que dicen es mentira y está cargado por el diablo. ¿Es tanto pedir que tengas fe ciega sin más?"

__________________

Claro que sé, y te iba a poner las faldas de bufanda igual que con el VIH.

Piensas que cambiando de tema te llevas la razón, bobalicona?

Hablamos de VIH o abres tu hilo para los gatos, viejuna?

Desde mi más absoluta ignorancia: referencias de esta afirmación?

__________________

Con mucho gusto.

Analicemos als cifras de VIH y SIDA que da el ministerio de la salud de Holanda:

Datos del Ministerio: Hoe vaak komt het voor en hoeveel mensen sterven eraan? - Nationaal Kompas Volksgezondheid

- Según el ministerio, en Diciembre del 2009 había 16.555 seropositivos registrados en Holanda.

- Según el ministerio, el 40% de los "infectados" no saben que lo están , es decir, 11.000 seropositivos más que no lo saben y por tanto no se medican con ARVs.

- Según el ministerio, en el 2008 murieron en Holanda 53 personas de SIDA.

Es decir, en el 2009 había 27.600 seropositivos, de los cuales solo 53 murieron de SIDA.

La pregunta es: son muchos muertos o pocos? Lo sabremos comparando la mortalidad por SIDA en seropostivos con la mortandad normal de la población en general:

La mortandad en Holanda es de 8,7 por cada 1.000 habitantes (ver Vraag: sterftecijfer), la media de la UE es de 9,2 por 1.000 habitantes.

Suponiendo que las terapias HAART son una maravilla y que todos las 53 muertos de SIDA se dan entre los 11.000 seropositivos que no se tratan porque desconocen su infección, llegamos a una mortandad por SIDA de solamente 4,8 por 1.000 seropositivos no tratados.

Está claro que aun en este escenario tan pesimista la mortandad por SIDA entre seropositivos no tratados es la mitad que la norma general. Esto quiere decir que prácticamente todos los seropositivos holandeses no tratados son "controladores de élite".

Conclusiones:

- Los "controladores de élite" son la regla y no la excepción como se nos quiere hacer creer.

- La ausencia de tratamiento no representa un riesgo de mortandad apreciable.

- El VIH/SIDA es un puto montaje para vender medicamentos a gente sana.

En Italia ocurre otro tanto de lo mismo. Se ha publicado este estudio al respecto en la revista médica revisada por pares "Medical Hypotheses"

Aids denialism at the ministry of health

Yo me ofrezco voluntario ante notario y las cámaras de televisión. Me inyecto lo que tú consideres que es VIH.

Como contrapartida tú aceptarías un tratamiento preventivo con antirretrovirales mientras yo siguiese sano o no contrajese ninguna de las enfermedades del síndrome SIDA.

Pondríamos un patrimonio en depósito, si no puedes con el tratamiento o te mueres me lo quedo todo yo, si me muero yo o enfermo de SIDA te lo llevas tú.

Hacemos el trato ya?

En España el tratamiento antirretroviral lo paga íntegramente la Seguridad Social, es 100% gratuíto para el paciente. En la mayoría de los países desarrollados sucede lo mismo o está subvencionado en un alto porcentaje por el gobierno.

Un tratamiento antirretroviral para una sola persona cuesta entre 6.000 y 18.000€ al año, lo cual, sólo en España, supone un gasto de 1000 millones de euros cada año. Dime: ¿tú crees que los gobiernos de los países más desarrollados permitirían ese despilfarro a cambio de nada?


Actualmente los tratamientos contra el VIH no tienen apenas efectos secundarios y existe uno con el cual sólo se administra una pastilla diaria. No creo que para nadie sea ningún problema seguir los tratamientos modernos, pero si tu información se quedó en el AZT y similares dinosaurios entiendo que sueltes frases de ese tipo.

__________________

No serás tan rastrera como para decir eso en serio...

Los nucleósidos análogos son los medicamentos más tóxicos que existen, provocando daños mitocondriales permanentes, daños neuronales, cáncer (mutaciones genéticas), fallos hepáticos y cardíacos.

Aquí está una lista de los devastadores efectos de esta QUIMIO PARA SANOS

Concerns about HAART (Highly Active Anti-Retroviral Therapy)

Adverse Effects with Nucleoside Analogs (‘Nukes’)

Nucleoside analogs emulate one of the four building blocks (nucleosides) of DNA, hence their name. Naturally such drugs interfere with DNA synthesis, causing problems with any organs or processes that rely on cell division, such as the replenishment of red and white blood cells. They also interfere with the energy regulating organelles known as mitochondria because they have their own DNA, without the protective mechanisms of the cell nucleus. It is most shocking that the most famous of these drugs, AZT, should be recommended for use by pregnant women. ...

“[Black box warning] LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, INCLUDING FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE ANALOGS ALONE OR IN COMBINATION WITH OTHER ANTIRETROVIRALS…Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported in association with the use of VIREAD…decreases in bone mineral density (BMD) were seen at the lumbar spine and hip…Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed…Immune reconstitution syndrome has been reported…the long term effects of TRUVADA are unknown…Selected Treatment-Emergent Adverse Events (Grades 2–4) Reported in 33% in Any Treatment Group in Study 934 (0–48 Weeks) [include] Diarrhea (7%), Nausea (8%), Fatigue (7%), Sinusitis (4%), URI (3%), Nasopharyngitis (3%), Sleepiness (3%), Headache (5%), Dizziness (8%), Depression (4%), Insomnia (4%), Abnormal dreams (4%), rash (5%)…Significant Laboratory Abnormalities Reported in ³1% of Patients in Any Treatment Group in Study 934…Any ³Grade 3 [serious] Laboratory Abnormality (25%), Fasting Cholesterol (15%), Creatine Kinase (7%), Serum Amylase (7%) [etc.]…other adverse events that occurred in at least 5% of patients receiving EMTRIVA or VIREAD with other antiretroviral agents in clinical trials include anxiety, arthralgia [joint pain], increased cough, dyspepsia [upset digestion], fever, myalgia [muscle pain], pain, abdominal pain, back pain, paresthesia [hallucination of any sense], peripheral neuropathy (including peripheral neuritis and neuropathy), pneumonia, rhinitis [inflamed nose] and rash event (including rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash and allergic reaction).”

Prescribing information for Truvada (emtricitabine and tenofovir disoproxil fumarate) tablets. Gilead. 2008 Nov


The most serious adverse event caused by abacavir is the hypersensitivity reaction, a severe allergic reaction that has been estimated to occur in around 8% of persons who begin abacavir therapy, usually within the first 6 weeks of treatment. Its multiform clinical manifestations include fever, rash, gastrointestinal, or respiratory symptoms, and may lead to life-threatening hypotension, renal failure and death, especially in the event of rechallenge with abacavir after a prior episode of hypersensitivity…In our patient, a potentially life-threatening neutropenia occurred 4 weeks after the start of abacavir therapy and was associated with fever, skin rash, and anaemia. The neutrophil count started to increase and themajority of clinical signs and symptoms resolved within 3–4 days after stopping abacavir, whereas absolute neutrophil count and haemoglobin level became normal after 10 days. Consistent clinical manifestations, a positive HLA-B 5701 testing, and the rapid recovery of our patient suggest that these adverse events may be immune mediated, probably due to the secretion of drug-related antibodies.”

Calza L et al. Abacavir-induced febrile agranulocytosis and anaemia. AIDS. 2008 Oct 18;22(16):2221-2

MENTECATA

“We describe a 62-year-old male who was diagnosed with HIV-1 in 2001 and died with lactic acidosis under treatment with didanosine [ddI/Videx] and stavudine [d4T/Zerit]…Lactic acidosis is a life-threatening complication of HAART. The onset is often abrupt, with uncharacteristic muscular, cardiac or hepatic symptoms. The outcome can be fatal due to liver failure and cardiac arrhythmia. Didanosine and stavudine are strong inhibitors of polymerase-gamma, which are known to induce mtDNA [mitochondrial DNA] depletion in subcutaneous adipose tissue and in liver”

Thoden J et al. Highly active antiretroviral HIV therapy-associated fatal lactic acidosis: quantitative and qualitative mitochondrial DNA lesions with mitochondrial dys******** in multiple organs. AIDS. 2008 May 31;22(9):1093-4


“[This study] included 1037 HIV-uninfected children born in 1991– 2002…Possible cases with unexplained signs of MD [mitochondrial dys********]…were identified through retrospective review. Associations between overall in utero NRTI [nucleoside reverse tran******ase inhibitor or 'nuke'] exposure, and trimester of first in utero NRTI exposure and possible MD were estimated…there were higher odds of first in utero exposure in the third trimester to lamivudine (3TC) and to zidovudine (ZDV [AZT]) and 3TC in combination (ZDV/3TC) among cases [of MD] than noncases. When adjusted for year of birth the odds of first exposure in the third trimester to 3TC [the risk was more than 10 times higher] and ZDV/3TC [was almost 10 times higher] were significantly higher among cases than non-cases…first exposure to 3TC or ZDV/3TC in the third trimester may be associated with the occurrence of possible MD”

Brogly SB et al. In utero nucleoside reverse tran******ase inhibitor exposure and signs of possible mitochondrial dys******** in HIV-uninfected children. AIDS. 2007 May 11;21(8):929-938

MENTECATA

The brain, peripheral nerves and other parts of the nervous system are often damaged by HAART.

“Although efavirenz is a universally recommended treatment for naive [naive=people who have never taken AIDS drugs before] HIV-infected individuals, neuropsychiatric adverse events are common…13 of 79 individuals (16.5%) in the etravirine arm and 36 of 78 individuals (46.2%) in the efavirenz arm showed at least one grade 1–4 drug-related treatment-emergent neuropsychiatric adverse event…The number with at least one grade 2–4 drug-related treatment-emergent neuropsychiatric adverse event was four of 79 individuals (5.1%) in the etravirine arm and 13 of 78 individuals (16.7%) in the efavirenz arm [there was no comparison with people not taking any medication]”

Nelson M et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS. 2011 Jan 28;25(3):335-40.

A comparison of neuropsychiatric adverse events during 12 we... : AIDS


“Of 1,651 HIV-infected patients assessed, 404 (24.5%) were identified as having one or more neurologic disorders, while 41%of AIDS-affected persons exhibited neurologic disease. Symptomatic distal sensory polyneuropathy (DSP, 10.0%) and HIV-associated neurocognitive disorder (HAND, 6.2%) represented the most prevalent disorders among 53 recognized neurologic disorders. Patients with at least one neurologic disorder exhibited higher mortality rates (17.6% vs 8.0%), particularly AIDS-related deaths (9.7% vs 3.2%), compared with those without neurologic disorders. The highest mortality HR [Hazard Ratio] was associated with opportunistic infections of CNS (HR 5.3), followed by HAND (HR 3.1) and the presence of any neurologic disorder (HR 2.0). The risk of AIDS-related death with a neurologic disorder was increased by 13.3% per 100 cells/mm3 decrement in blood CD4 T-cell levels or by 39% per 10-fold increment in plasma viral load [no information was given on AIDS drug use by the participants in this trial]”

Vivithanaporn P et al. Neurologic disease burden in treated HIV/AIDS predicts survival. Neurology. 2010 Sep 28


“Antiretroviral regimens with good CNS penetration, as assessed by CPE rank, are more effective in controlling CSF (and presumably CNS) viral replication than regimens with poorer penetration. In this study, antiretrovirals with good CNS penetration were associated with poorer neurocognitive performance. A larger controlled trial is required before any conclusions regarding the influence of specific antiretrovirals on neurocognitive performance should be made [Exactly, never stop the drugs even if they are killing your patients]”

Marra CM et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009 Jul 17;23(11):1359-66.

MENTECATA

Cancer is quite commonly associated with the use of HAART.

“Risk factors for death in patients diagnosed with non-Hodgkin’s lymphoma in the era of combination antiretroviral therapy…[risk related to status of combination Anti-Retroviral Therapy] No: 1 [baseline]; Yes for <90 days: 1.42 [times greater risk than those not using this therapy]; Yes for ³90 days: 1.98 [times greater risk than those not using this therapy]…Patients who developed NHL while not on cART had better survival, particularly when compared with patients who developed NHL after receiving cART for 90 days or more.”

Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS. 2009 Sep 24;23(15):2029-37.


“Among 86 322 patients included in the analysis, 132 had a diagnosis of anal cancer…102 occurred in the recent cART [combination Anti-Retroviral Therapy] period (1999– 2004)…The median CD4 cell count at anal cancer diagnosis increased with time from 188 cells/µl in the precART period to 288 cells/µl in the recent cART period. Nearly one-quarter of the patients had not received cART before the onset of anal cancer [i.e. more than three-quarters had received AIDS drugs]…In the precART, the early cART and the three sub-periods of the recent cART era (1999–2000, 2000–2001 and 2002–2003), the incidences of anal cancer were 10.5, 18.4, 43.1, 36.3 and 39.3 per 100 000 person-years, respectively.”

Piketty C et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS. 2008 Jun 19;22(10):1203-11.


“Dramatic declines in KS [Kaposis Sarcoma] and NHL [Non-Hodgkins Lymphoma] were temporally related to improving therapies, especially introduction of HAART, but those with AIDS remain at marked risk. Among non-AIDS-related cancers, a recent increase in Hodgkin lymphoma was observed…Risk of Hodgkin Lymphoma increased substantially over the 1990-2002 period [8.1 times higher than the general population in 1990-5 and 13.6 times higher in 1996-2002]…[Table 2 shows that the risk of all non-AIDS associated cancers was double (compared to the general population) in 1980-9, 1.8 times higher in 1990-5 and 1.7 times higher in 1996-2002. Why would the risk of non-AIDS cancers be higher?]”

Engels EA et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006 Aug 1;20(12):1645-1654.


“With the advent of HAART there has been a dramatic decline in the incidence of Kaposi's Sarcoma [this may be a false association as many other things have changed, including usage patterns of nitrite inhalants]. However, the existence of B cell related lymphomas has not declined to the same extent…Bonnet et al noted that malignancies were the cause of death in 28% of HIV infected patients who died in 2000. Of 964 deaths, solid cancers accounted for 103 cases and included 50 lung, 19 hepatocellular [liver], 9 digestive and 6 anal cancers. The authors also reported 17 non-HIV-related hematological [blood] cancers.”

Pulvirenti JJ. Inpatient care of the HIV infected patient in the highly active antiretroviral therapy (HAART) era. Curr HIV Res. 2005 Apr;3(2):133-45.